MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs): FINDINGS FROM THE 2012 G-FINDER REPORT.

MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs):

FINDINGS FROM THE 2012 G-FINDER REPORT

Policy Cures

Innovative ideas and accurate analysis to accelerate development and uptake of new drugs, vaccines, diagnostics and other products for neglected diseases of the developing world

• Annual survey of global investment into R&D of new neglected disease products

• Neutral, comparable, comprehensive analysis

• Commissioned by the Bill & Melinda Gates Foundation

• 31 neglected diseases• 134 product areas• All R&D stages

G-FINDER

$84.9m higher in 2011 than in 2007

Malaria – overall funding

Malaria – by product area

• Vaccines, diagnostics and vector control R&D ↑

• Drug R&D →

• Basic research ↑

Who funds malaria R&D?

Gates Foundation 26.3%

US NIH 20.7%

Industry (aggregate) 18.7%

66%

NTDs

50% 65%

Buruli ulcer

Dengue

Kinetoplastids (Chagas, HAT, leishmaniasis)

Helminths (lymphatic filariasis, STHs, cysticercosis, onchocerciasis, schistosomiasis)

Leprosy

Trachoma

HIV/AIDS

Malaria

TB

Diarrhoeal diseases

Bacterial pneumonia & meningitis

Salmonella infections

Rheumatic fever

Guinea worm disease

Echinococcosis

Foodborne trematode infections

Rabies

Yaws

WHO classification G-FINDER

NTDs – dengue, kinetoplastids and helminths

NTDs – leprosy, Buruli ulcer and trachoma

$7.4m$5.8m $9.6m

Download the full report atwww.policycures.org/g-finder2012.html